Abstract
BackgroundBispecific antibodies have shown significant promise as therapies for various cancers.1 ATG101 is a bispecific antibody that crosslinks tumor-expressed PD-L1 to T-cell-expressed 4-1BB, thereby selectively activating tumor-infiltrating T-cells while inhibiting...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have